Technology

To be specific Peptas Pharma is expertized in the development of transdermal patches –

The production of transdermal patches is a continuous and artisanal process that consists of 3 stages that reflect how delicate and specific is the production of this niche pharmaceutical form. Let´s review it!

Transdermal patches of the drug-in-adhesive type are pharmaceutical forms that deliver an active ingredient through the transdermal route. They consist of: a support layer, an adhesive matrix containing the active ingredient and a release layer that is discarded when the product is applied to the skin.

The manufacturing process consists of the following stages:

Mixing
Coating, Drying and Laminating
Die-cutting and Packaging

1. Mixing

It represents the beginning of the manufacturing process and its objective is to achieve the integration of the active and non-active ingredients that make up the formulation.

The following materials are normally involved in this process:

API (Active Pharmaceutical Ingredient) and functional and non-functional excipients. The semi-finished product resulting from this phase being the Mix according to the formulation.

At this stage it is important to control the correct dissolution and dispersion of the components to guarantee the homogeneity of the adhesive mixture necessary to ensure the correct dosage and that all the units produced are effective and safe because of the controlled release of the active ingredient.

2. Coating, Drying and Laminating

Once the mixture is obtained, the following process consists of three sub-stages: first is the coating, which is a continuous process where the mixture is uniformly dispensed on the release liner.

Subsequently, both components go through various drying stations in order to evaporate the volatile components of the mixture, in order to obtain the “adhesive mixture”.

Finally, both components are joined at the exit of the drying stations with the backing film, thus obtaining the multilayer system that forms the transdermal system (backing film-adhesive matrix-release liner).

Typically, the raw materials for this phase are: the mixture (semi-finished resulting from the previous stage), the release liner and the backing film. Obtaining the resulting semi-finished product: one or more laminate rolls.

3. Die-cutting and packaging

The next and last process is the die- cutting and packaging of the transdermal patches. In this stage, the shape of the patch itself is obtained with the surface established according to the dose. This process is carried out by die cutting the layers obtained in the previous process where several cuts are generally made, one of them being the cut for easy detachment, therefore allowing the patient to open the patch and then to apply it on the safer and more practical area of the skin.

Conculsion

As we reviewed, the 3 stages of transdermal patch production require specific adjustments associated with experience, which determines that this is one of the most artisanal pharmaceutical forms available in the industry. This is why, if you or your company are considering working on a transdermal patch development and manufacturing project, it is very important to work with a professional and experienced partner who can demonstrate sufficient knowledge to ensure the necessary quality of this production

Transdermal Drug Delivery Systems(TDDS)

Transdermal drug delivery systems (TDDS, “Patch”) are self-contained, discrete dosage forms that, when applied to intact skin, are designed to deliver the drug(s) through the skin to the systemic circulation.
Transdermal dosage form is well known for the delivery of pain medicine, smoking cessation, and hormone therapy.

Advantages:

Metabolism Enhancing bioavailability via bypassing first pass
Reduction of systemic side effects
Maintenance of steady plasma level of the drug
Enhancement of therapeutic efficiency
Increasing Patient compliance

Expertise:

Development of both single and multi-layered patches of TDDS to achieve desired pharmacokinetic profiles for specialized drug delivery up to a week
Development of drug-in-adhesive patches for transdermal drug delivery of both branded (505 b2) and generic pharmaceutical applications.

Upcoming Innovations -

We are focused on formulating and developing high-barrier-to-entry Transdermal Drug Delivery systems (TDDs) for ANDA, NDA, and 505(b)(2) applications.

Our expert team has unrivaled experience in designing, producing, and bringing custom patches to market. Slitting, coating, and printing to final fulfillment, our team will seamlessly integrate into yours to collaborate on producing the perfect patch for the modern market

Products Under Development - TRANSDERMAL PATCHES – PHARMACEUTICAL